Genevieve McHugh
Family · New York, NYNPI 1841846821
Payments from drug & device makers
Across 108 payments — averaging $35.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$977
- Novo Nordisk$735
- AstraZeneca$560
- Pfizer$498
- Amgen$318
- Novartis$163
- plus $618 from 12 others
What the payments were for
- Travel & lodging$972%
- Food & beverage$3,77498%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $977 |
| Novo Nordisk | 17 | $735 |
| AstraZeneca | 18 | $560 |
| Pfizer | 23 | $498 |
| Amgen | 14 | $318 |
| Novartis | 3 | $163 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Medtronic | 3 | $91 |
| E.r. Squibb & Sons, L.L.C. | 3 | $73 |
| Johnson & Johnson | 3 | $69 |
| Kestra Medical Technology Services, Inc. | 1 | $57 |
| Chiesi USA, Inc. | 2 | $48 |
| Edwards Lifesciences | 1 | $39 |
| Boehringer Ingelheim | 1 | $35 |
| Bayer | 1 | $27 |
| Merck | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$366
- MitraClip$309
- WAINUA$250
- LEQVIO$125
- AMPLATZER AMULET$120
How this compares
$3,871 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 121 | $85,490 |
| EliquisApixaban | 122 | $82,454 |
| BrilintaTicagrelor | 99 | $72,559 |
| JardianceEmpagliflozin | 21 | $17,597 |
| ClopidogrelClopidogrel Bisulfate | 760 | $7,790 |
| Prasugrel Hcl | 88 | $6,135 |
| Pantoprazole Sodium | 665 | $3,225 |
| Rosuvastatin Calcium | 71 | $1,204 |
| Atorvastatin Calcium | 113 | $1,182 |
| Metoprolol Succinate | 102 | $720 |
| Mirtazapine | 15 | $392 |
| Famotidine | 48 | $378 |
| Nifedipine ErNifedipine | 20 | $252 |
| Colchicine | 11 | $203 |
| Amiodarone Hcl | 19 | $181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $69 | $85,490121 claims |
| PfizerEliquis | $498 | $82,454122 claims |
| AstraZenecaBrilinta | $560 | $72,55999 claims |
| Boehringer IngelheimJardiance | $35 | $17,59721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.
Other family in New York
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Mary Sullivan-WhalenNew York$137K
- Leslie WoronaNew York$77K
- Thomas SaglimbeniNew York$48K
- Kathryn JohnsonNew York$48K
- Derek PinedaNew York$38K
- Rebecca SchoriNew York$32K
- Evangelia NezisNew York$22K
- Colette NelsonNew York$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.